Showing results (551-560 of 610) with videos related to

Sort By:
Pageof 61
JCO Precision Oncology|September 15, 2018
Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring anAnna F Farago, Martin S Taylor, Robert C Doebele, et al.
The New England Journal of Medicine|March 28, 2014
Ceritinib in ALK-rearranged non-small-cell lung cancerAlice T Shaw, Dong-Wan Kim, Ranee Mehra, et al.
NPJ Precision Oncology|August 18, 2020
Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibitionJessica J Lin, Adam Langenbucher, Pranav Gupta, et al.
Cancer Discovery|August 11, 2018
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front MutationsAlexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2020
U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid TumorsKyriakos P Papadopoulos, Erkut Borazanci, Alice T Shaw, et al.
Cancer Discovery|March 29, 2014
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancerLuc Friboulet, Nanxin Li, Ryohei Katayama, et al.
The New England Journal of Medicine|December 25, 2015
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198FAlice T Shaw, Luc Friboulet, Ignaty Leshchiner, et al.
Science Translational Medicine|March 25, 2011
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitorsLecia V Sequist, Belinda A Waltman, Dora Dias-Santagata, et al.
Nanoscale|April 7, 2012
Large-scale parallel arrays of silicon nanowires via block copolymer directed self-assemblyRichard A Farrell, Niall T Kinahan, Stefan Hansel, et al.
The New England Journal of Medicine|June 4, 2013
Crizotinib versus chemotherapy in advanced ALK-positive lung cancerAlice T Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, et al.
Pageof 61